Response to Anti-hypertensives in Pregnant and Postpartum Patients

• Status: Completed
• Trial end date: 2019-04-05
• Target enrollment: 0
• Participant gender: Female

Summary

In this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure defined as greater than 160/110. These anti-hypertensives are first line therapy for management of severe range blood pressures in pregnancy and postpartum by the American Congress of Obstetricians and Gynecologist (ACOG). In addition at the Mount Sinai West site, the investigators will also analyze the ADRB1 and similar genes involved in beta blockade, genes involved in calcium channel blockade and other genes implicated in blood pressure response among pregnant and postpartum patients receiving labetalol and nifedipine. This analysis will be used to determine if a pharmacogenetic association exists between variant alleles in these receptors in the pregnant and postpartum population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai
• Collaborators: Maimonides Medical Center; Mount Sinai Hospital, New York
• Treatments: Antihypertensive Agents; Labetalol; Nifedipine

Criteria

Inclusion Criteria:

• pregnant patients from 20 weeks to up to 6 weeks postpartum

• between the ages of 18-55.

• persistent severe range blood pressures (2 readings or more within 15 minutes) of either 160mmHg systolic or 110mmHg diastolic.

Exclusion Criteria:

• multiple gestation

• patients with non-reassuring fetal heart rate (category 3)

• patients with abruptio placenta

• patients with renal impairment

• history of heart failure

• history of cardiac arrhythmia

• use of anti-hypertensive medications in the past 24 hours

• patients with allergies or medical contraindications to labetalol or nifedipine.